Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Impact of co-existent thyroiditis on clinical outcome in papillary thyroid carcinoma with high preoperative serum antithyroglobulin antibody: a retrospective cohort study
Objectives
The aim of this study was to investigate the impact of co‐existent chronic lymphocytic thyroiditis (CLT) on changes in serum antithyroglobulin antibody (TgAb) and clinical outcome in papillary thyroid carcinoma (PTC) patients with high preoperative serum TgAb.
Design
A retrospective cohort study.
Setting
University teaching hospital.
Participants
Thirty‐seven PTC patients with high preoperative serum TgAb level (≥100 U/mL) were evaluated. All patients underwent total thyroidectomy followed by high‐dose I‐131 ablation.
Main outcome measures
Per cent changes of TgAb between pre‐treatment and post‐treatment, and disease‐free survival were calculated.
Results
Twenty‐two patients (59.5%) had co‐existent CLT, and seven had residual/recurrent tumours. There was a higher proportion of females among the patients with CLT compared to those without CLT (95.5% versus 66.7%; P = 0.0306). There were trends towards more aggressive pathologies, such as tumour size, extrathyroidal extension, surgical margin and lymph node stage, in PTC without CLT than in that with co‐existent CLT. Pre‐treatment and post‐treatment TgAb were all higher in PTC with co‐existent CLT. But, per cent changes of TgAb between pre‐treatment and post‐treatment were no significant difference between PTC with and without CLT (P < 0.05). Patients with co‐existent CLT showed a significantly lower residual/recurrent tumour rate than those without CLT (4.5% versus 40%; P = 0.0113).
Conclusion
Residual/recurrent tumour rate was lower in PTC patients with co‐existent CLT than in those without CLT.